Scholars@Duke
Anne Louise Marano

Anne Louise Marano

Associate Professor of Dermatology
Dermatology
anne.marano@duke.edu
DUMC 3135, Durham, NC 27710
234 Crooked Creek Parkway, Durham, NC 27713

Selected Publications

The role of the environment in allergic skin disease.

Journal Article Curr Allergy Asthma Rep · June 2024 PURPOSE OF REVIEW: This paper explores how environmental factors influence allergic skin diseases, including atopic dermatitis (AD), contact dermatitis (CD), urticaria, angioedema, and reactions to drugs and insect bites. RECENT FINDINGS: Research indicate ... Full text Link to item Cite

Inpatient Management of Autoimmune Blistering Diseases: an Update, Review, and Practical Guide

Journal Article Current Dermatology Reports · December 1, 2019 Purpose of Review: Review the evaluation, management, and treatment of hospitalized autoimmune blistering diseases (AIBD) patients based on the current literature and expert opinion. Recent Findings: The cost and prevalence of hospitalization for AIBD pati ... Full text Cite

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.

Journal Article Br J Dermatol · September 2019 Programmed cell death 1 (PD-1) blockade has rapidly emerged as an effective therapy for a wide variety of metastatic malignancies. It has been associated with multiple immune-related adverse effects, including cutaneous eruptions. We describe two patients ... Full text Link to item Cite

Cutaneous disease in kidney transplantation patients

Chapter · January 1, 2019 Kidney transplant patients are at an increased risk of developing cutaneous disease due to immunosuppression and medication side effects. In particular, this chapter will focus on the extremely important burden of higher rates of cutaneous malignancy in ki ... Full text Cite

Nodular amyloidosis in a patient with systemic scleroderma.

Journal Article Dermatol Online J · September 15, 2018 Primary cutaneous amyloidosis may be characterized as macular amyloidosis, lichenoid amyloidosis, or nodular amyloidosis. Nodular amyloidosis results from the deposition of immunoglobulin light chains and may rarely be associated with systemic amyloidosis. ... Open Access Link to item Cite

Fever, Joint Pain, Seizures, and Rash in a 53-Year-Old Woman.

Journal Article Arthritis Care Res (Hoboken) · September 2017 Full text Link to item Cite

Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy.

Journal Article J Invest Dermatol · June 2014 Metastatic melanoma often relapses despite cytotoxic treatment, and hence the understanding of melanoma tumor repopulation is crucial for improving our current therapies. In this study, we aim to define the role of caspase 3 in melanoma tumor growth after ... Full text Link to item Cite

Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy

Journal Article Journal of Investigative Dermatology · January 1, 2014 Metastatic melanoma often relapses despite cytotoxic treatment, and hence the understanding of melanoma tumor repopulation is crucial for improving our current therapies. In this study, we aim to define the role of caspase 3 in melanoma tumor growth after ... Full text Cite

The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

Journal Article Cancer Res · February 1, 2010 The G protein-coupled receptor GPR30 binds 17beta-estradiol (E(2)) yet differs from classic estrogen receptors (ERalpha and ERbeta). GPR30 can mediate E(2)-induced nongenomic signaling, but its role in ERalpha-positive breast cancer remains unclear. Gene e ... Full text Link to item Cite

Kidney transplantation

Chapter · December 1, 2008 In 2002 in the United States, 431,281 patients received treatment for end-stage renal disease (ESRD), including 308,910 on dialysis and 122,374 with a functioning renal transplant.1 The prevalence of ESRD is increasing at an annual rate of 4%, down from 9% ... Full text Cite

Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen.

Journal Article Mol Cancer Ther · November 2007 Aromatase inhibitors (AI) are being evaluated as long-term adjuvant therapies and chemopreventives in breast cancer. However, there are concerns about bone mineral density loss in an estrogen-free environment. Unlike nonsteroidal AIs, the steroidal AI exem ... Full text Link to item Cite